CoChat

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer

Open access
Nicolle, Rémy, Blum, Yuna, Duconseil, Pauline, Vanbrugghe, Charles, Brandone, Nicolas, Poizat, Flora, Roques, Julie, Bigonnet, Martin, Gayet, Odile, Rubis, Marion, Elarouci, Nabila, Armenoult, Lucile, Ayadi, Mira, de Reyniès, Aurélien, Giovannini, Marc, Grandval, Philippe, Garcia, Stephane, Canivet, Cindy, Cros, Jérôme, Bournet, Barbara, Buscail, Louis, Moutardier, Vincent, Gilabert, Marine, Iovanna, Juan, Dusetti, Nelson · 2020 · EBioMedicine
Cited by 93

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Abstract BACKGROUND A significant gap in pancreatic ductal adenocarcinoma (PDAC) patient’s care is the lack of molecular parameters characterizing tumors and allowing a personalized treatment. The goal of this study was to examine whole PDAC transcriptomic profiles to define a signature that would predict aggressiveness and treatment responsiveness better than done until now. METHODS AND PATIENTS Tumors were obtained from 76 consecutive resectable (n=40) or unresectable (n=36) tumors. PDAC were transplanted in mice to produce patient-drived xenografts (PDX). PDX were classified according to their histology into five groups, from highly undifferentiated to well differentiated. This classification resulted strongly associated with tumors aggressiveness. A PDAC molecular gradient (PAMG) was constructed from PDX transcriptomes recapitulating the five histological groups along a continuous gradient. The prognostic and predictive value for PMAG was evaluated in: i/ two independent series (n=598) of resected tumors; ii/ 60 advanced tumors obtained by diagnostic EUS-guided biopsy needle flushing and iii/ on 28 biopsies from mFOLFIRINOX treated metastatic tumors. RESULTS A unique transcriptomic signature (PAGM) was generated with significant and independent prognostic value. PAMG significantly improves the characterization of PDAC heterogeneity compared to non-overlapping classifications as validated in 4 independent series of tumors (e.g. 308 consecutive resected PDAC, HR=0.321 95% CI [0.207;0.5] and 60 locally-advanced or metastatic PDAC, HR=0.308 95% CI [0.113;0.836]). The PAMG signature is also associated with progression under mFOLFIRINOX treatment (Pearson correlation to tumor response: -0.67, p-value < 0.001). CONCLUSION We identified a transcriptomic signature (PAMG) that, unlike all other stratification schemas already proposed, classifies PDAC along a continuous gradient. It can be performed on formalin-fixed paraffin-embedded samples and EUS-guided biopsies showing a strong prognostic value and predicting mFOLFIRINOX responsiveness. We think that PAMG could unify all PDAC preexisting classifications inducing a shift in the actual paradigm of binary classifications towards a better characterization in a gradient. Trial Registration The PaCaOmics study is registered at www.clinicaltrials.gov with registration number NCT01692873 . The validation BACAP study is registered at www.clinicaltrials.gov with registration number NCT02818829 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2020.102858

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 93

Metadata

Authors
Nicolle, R., Blum, Y., Duconseil, P., Vanbrugghe, C., Brandone, N., Poizat, F., Roques, J., Bigonnet, M., Gayet, O., Rubis, M., Elarouci, N., Armenoult, L., Ayadi, M., de Reyniès, A., Giovannini, M., Grandval, P., Garcia, S., Canivet, C., Cros, J., Bournet, B., Buscail, L., Moutardier, V., Gilabert, M., Iovanna, J., & Dusetti, N.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2020-07
Volume
57
Pages
102858
ISSN
2352-3964 (ISSN-L)
OpenAlex
W3039702151
Cited by
93
References
10
FWCI
5.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. https://app.cochat.ai/papers/10.1016/j.ebiom.2020.102858
The paper
Nicolle, R., Blum, Y., Duconseil, P., Vanbrugghe, C., Brandone, N., Poizat, F., Roques, J., Bigonnet, M., Gayet, O., Rubis, M., Elarouci, N., Armenoult, L., Ayadi, M., de Reyniès, A., Giovannini, M., Grandval, P., Garcia, S., Canivet, C., Cros, J., . . . Dusetti, N. (2020). Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. EBioMedicine. https://doi.org/10.1016/j.ebiom.2020.102858

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.